Catalent

The Global Biotechnology Contract Manufacturing Market is projected to grow from USD 15.38 Bn in 2022 to USD 30.87 Bn by 2031, driven by factors like access to expensive technologies, increased flexibility, and speedy product introductions. Key players include Lonza, Samsung Biologics, Thermo Fisher Scientific, and others. The market faces challenges like labeling and packaging issues. The Asia Pacific region shows significant growth potential due to rising R&D investments and healthcare infrastructure improvements.

Catalent, Inc. and Novo Holdings A/S have fulfilled all regulatory closing conditions for their pending transaction, expected to close in the coming days. Catalent's CEO, Alessandro Maselli, expressed excitement for the company's future under Novo Holdings' ownership, emphasizing innovation and enhanced offerings. Jonathan Levy, Senior Partner at Novo Holdings, highlighted the benefits of the transaction for driving healthcare innovation and improving patient outcomes.

Global clinical trial supply and logistics market size was USD 3.98 billion in 2024, projected to reach USD 7.85 billion by 2033, growing at a CAGR of 7.79%. Key takeaways include North America's 36.15% market share in 2023, logistics & distribution segment dominance with 27.68% revenue share, phase III segment holding 40.38% revenue share, pharmaceuticals segment generating 42.11% revenue share, and cardiovascular diseases segment accounting for 32.34% market share. Major trends include growing clinical trials, effective supply management, increasing third-party organizations, and AI usage in supply chain operations.

The clinical trial supply and logistics market was valued at USD 4.03 billion in 2024 and is projected to reach USD 7.94 billion by 2033. Key trends include the shift to decentralized clinical trials (DCTs), increasing use of advanced technologies like AI and blockchain, and a focus on personalized treatments. North America dominates the market, while Asia Pacific is the fastest-growing region. Major players include Almac Group, Ltd, Catalent, Inc., Ceva Logistics, AG, and Thermo Fisher Scientific, Inc.

The Pharmaceutical Contract Manufacturing Market is projected to exceed $155 billion in 2024, driven by high in-house drug development costs and varying regulatory requirements. CDMOs like Thermo Fisher Scientific and Samsung Biologics are expanding services to meet demand, offering end-to-end solutions from development to commercial-scale manufacturing. The market report provides revenue forecasts to 2034, regional and national market analyses, and profiles of leading companies.

The Life Sciences BPO market is projected to reach $557.8B by 2030, driven by demand for cost-effective solutions, regulatory complexity, and technological advancements like AI and automation.

The Biotechnology Contract Manufacturing Market is projected to grow from $16.28 Bn in 2023 to $31.05 Bn by 2031, driven by increasing demand for biopharmaceuticals, rising R&D investments, and advancements in bioprocessing technologies. Key drivers include the use of biologics in various therapeutic areas and the demand for personalized medicine. Challenges include high manufacturing costs, regulatory compliance, and intellectual property risks. Prominent players include Lonza, Samsung Biologics, and Thermo Fisher Scientific.

Orbis Research report analyzes Biotechnology Contract Manufacturing Market, detailing market segmentations, product analysis, R&D developments, supply chain dynamics, and expert opinions. Special focus on geopolitical impacts, key players, and strategic insights.